Study | Research Studies | School of Medicine

NAUTIKA1: A MULTICENTER, PHASE II, NEOADJUVANT AND ADJUVANT STUDY OF MULTIPLE THERAPIES IN BIOMARKER-SELECTED PATIENTS WITH RESECTABLE STAGES IB-III NON-SMALL CELL LUNG CANCER

Primary Objective

Study ML41591, is an umbrella trial that will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, selected IIIB (only T3N2) (8th edition AJCC TNM staging) resectable and untreated NSCLC tumors that meet protocol specified biomarker criteria determined in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.

Is This Study For You?

Let's Get Started!

Description

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria.

Details

Age

Adult

Eligibility

Are 18 years of age or older, have a diagnosis of Early Stage Non-Small Cell Lung Cancer, have a specific molecular alteration which will be determined by lab tests, will have surgery to remove the cancer, have adequate Lung and Heart Function Additional requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov.

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator

Tejas Patil

Study ID

Protocol Number: 22-1484

More information available at ClinicalTrials.gov: NCT04302025

Is this Study for You?